2024
PLUS-IS-LESS project: Procalcitonin and Lung UltraSonography-based antibiotherapy in patients with Lower rESpiratory tract infection in Swiss Emergency Departments: study protocol for a pragmatic stepped-wedge cluster-randomized trial
Bessat C, Bingisser R, Schwendinger M, Bulaty T, Fournier Y, Della Santa V, Pfeil M, Schwab D, Leuppi J, Geigy N, Steuer S, Roos F, Christ M, Sirova A, Espejo T, Riedel H, Atzl A, Napieralski F, Marti J, Cisco G, Foley R, Schindler M, Hartley M, Fayet A, Garcia E, Locatelli I, Albrich W, Hugli O, Boillat-Blanco N. PLUS-IS-LESS project: Procalcitonin and Lung UltraSonography-based antibiotherapy in patients with Lower rESpiratory tract infection in Swiss Emergency Departments: study protocol for a pragmatic stepped-wedge cluster-randomized trial. Trials 2024, 25: 86. PMID: 38273319, PMCID: PMC10809691, DOI: 10.1186/s13063-023-07795-y.Peer-Reviewed Original ResearchConceptsPrescription of antibioticsRespiratory tract infectionsLung ultrasoundSwiss emergency departmentEmergency departmentTract infectionsAntibiotic prescriptionsProportion of patients prescribed antibioticsBackgroundLower respiratory tract infectionsCluster-randomizedSide effectsAntibiotic-related side effectsLower respiratory tract infectionsLength of hospital stayPatients prescribed antibioticsClinical severity scoreClinical prediction scoreProportion of patientsReducing antibiotic prescriptionsCo-primary endpointsChest X-rayDecrease side effectsPreserving patient safetyPattern of pneumoniaProportion of antibiotics
2023
Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study
Miauton A, Audran R, Besson J, Hajjami H, Karlen M, Warpelin-Decrausaz L, Sene L, Schaufelberger S, Faivre V, Faouzi M, Hartley M, Spertini F, Genton B. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. EBioMedicine 2023, 99: 104922. PMID: 38128414, PMCID: PMC10776924, DOI: 10.1016/j.ebiom.2023.104922.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cellsDouble-blindIntention-to-treatVehicle-controlledAdverse eventsVirus-specific CD8+ T cellsPeptide vaccinesCD8+ T cell immunityInjection site erythemaInjection site painT cell immunityPhase 1 studyPhase 1 trialDengue vaccine candidateAnti-DENV antibodiesAntibody-dependent enhancementSite painSevere dengueGlobal health threatCentral memoryPrimary outcomeCD8Microneedle injectionInduced antibodies
2022
Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center
Schaad S, Brahier T, Hartley M, Cordonnier J, Bosso L, Espejo T, Pantet O, Hugli O, Carron P, Meuwly J, Boillat-Blanco N. Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center. BMJ Open 2022, 12: e060181. PMID: 35750462, PMCID: PMC9234434, DOI: 10.1136/bmjopen-2021-060181.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionLung ultrasoundClinical findingsCOVID-19Early identificationCOVID-19 positive patientsAbnormal LUS findingsBlinded independent expertsProspective observational cohortMild COVID-19Healthy healthcare workersCare lung ultrasonographyLausanne University HospitalAppropriate screening toolSARS-CoV-2COVID-19 screeningLUS featuresLUS findingsObservational cohortProspective cohortSymptom onsetAbnormal findingsClinical featuresLung ultrasonographyLung zones
2020
Lung Ultrasonography for Risk Stratification in Patients with Coronavirus Disease 2019 (COVID-19): A Prospective Observational Cohort Study
Brahier T, Meuwly J, Pantet O, Vez M, Donnet H, Hartley M, Hugli O, Boillat-Blanco N. Lung Ultrasonography for Risk Stratification in Patients with Coronavirus Disease 2019 (COVID-19): A Prospective Observational Cohort Study. Clinical Infectious Diseases 2020, 73: e4189-e4196. PMID: 32940646, PMCID: PMC7543331, DOI: 10.1093/cid/ciaa1408.Peer-Reviewed Original ResearchConceptsLung ultrasonographyCoronavirus disease 2019Emergency departmentLUS scoreRisk stratificationDisease 2019Lower respiratory tract infectionsProspective observational cohort studyPleural line irregularitiesEarly risk stratificationObservational cohort studyProspective observational studyRespiratory tract infectionsRisk stratification toolConfluent B-linesDifferent clinical outcomesLausanne University HospitalCOVID-19B-linesLUS characteristicsLUS findingsCohort studyTract infectionsClinical outcomesPatient group
2017
Predicting Ebola Severity: A Clinical Prioritization Score for Ebola Virus Disease
Hartley M, Young A, Tran A, Okoni-Williams H, Suma M, Mancuso B, Al-Dikhari A, Faouzi M. Predicting Ebola Severity: A Clinical Prioritization Score for Ebola Virus Disease. PLOS Neglected Tropical Diseases 2017, 11: e0005265. PMID: 28151955, PMCID: PMC5289426, DOI: 10.1371/journal.pntd.0005265.Peer-Reviewed Original ResearchConceptsEbola virus diseaseViral loadPrognostic toolEbola viral loadMultivariate prognostic scoreRetrospective cohort studyEbola treatment centersAccurate prognostic toolVirus diseaseEVD mortalityClinical characteristicsCohort studyPrognostic scoreAsymptomatic infectionClinical severityIntensive treatmentPrognostic potentialUnadjusted predictorsDisease scoreMortality rateTreatment centersEVD diagnosisMortality risk reductionDeadly infectionEarly reporting
2015
Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse
Bourreau E, Ginouves M, Prévot G, Hartley M, Gangneux J, Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A, Pratlong F, Martin R, Schütz F, Couppié P, Fasel N, Ronet C. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. The Journal Of Infectious Diseases 2015, 213: 105-111. PMID: 26123564, DOI: 10.1093/infdis/jiv355.Peer-Reviewed Original ResearchConceptsL. guyanensis infectionLeishmania RNA virus 1American tegumentary leishmaniasisSymptomatic relapseTreatment failureTegumentary leishmaniasisFirst-line treatment failureDoses of pentamidineLeishmania guyanensis infectionLine treatment failureFirst-line treatmentChronic cutaneous leishmaniasisVirus 1Second-line drugsExperimental murine leishmaniasisInflammatory markersHyperinflammatory responseExtended therapyMurine leishmaniasisTherapeutic choiceSuch complicationsRNA virus 1Persistent infectionCutaneous leishmaniasisRelapse